Scotiabank Cuts Knight Therapeutics Inc (GUD) Price Target to C$9.50
Knight Therapeutics Inc (TSE:GUD) had its price objective decreased by Scotiabank from C$10.00 to C$9.50 in a research note published on Friday morning, StockTargetPrices.com reports. Scotiabank currently has an outperform rating on the stock.
Separately, CIBC upped their target price on shares of Knight Therapeutics from C$9.50 to C$9.80 in a research note on Friday, November 11th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of C$9.83.
Knight Therapeutics (TSE:GUD) opened at 9.78 on Friday. Knight Therapeutics has a 1-year low of $5.89 and a 1-year high of $9.86. The firm has a market cap of $1.30 billion and a price-to-earnings ratio of 68.87. The company’s 50 day moving average is $9.20 and its 200-day moving average is $8.65.
Knight Therapeutics Company Profile
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.
Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.